Short answer
Cryoport, Inc. (CYRX) filed its Q1 2026 10-Q quarterly report on May 5, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $48M (up 16.5% year over year) with net income of −$11M.
Q1 2026 key financials · XBRL
- Revenue
- $48M
- +16.5% YoY
- Net income
- −$11M
- +12.0% YoY
- Operating margin
- -20.1%
- Gross margin
- 45.8%
- EPS (diluted)
- −$0.25
- +10.7% YoY
Source: XBRL data from the Cryoport, Inc. (CYRX) Q1 2026 10-Q on SEC EDGAR. USD.
Cryoport, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No profitability, margin, cash-flow, or capital-deployment figures provided in supplied excerpt
- Headwinds: supply-chain constraints, inflation, tariffs, foreign-exchange volatility, geopolitical conditions, including war with Iran
- Outlook: anticipated cell-and-gene-therapy market expansion and potential acquisition opportunities
- CRYOPDP divestiture and DHL partnership: disruption risks affecting employees, suppliers, and business relationships
Risk Factors
- No material changes disclosed from 2025 Annual Report risk factors
- Carried-forward business risks could materially adversely affect operations and financial condition
- Unknown or currently immaterial risks could also adversely affect results
- No new regulatory, legal, liquidity, debt, currency, or concentration risks identified in the quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Cryoport, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.